复方嗜乳酸杆菌对合并胃肠道症状的腹膜透析患者IL-17、VEGF及TGF-β_(1)的影响  

作　　者：王一亭 王夏颖 王宇晖[1] 翁宁[1] 童孟立[1] 

机构地区：[1]浙江中医药大学附属杭州市中医院,310053

出　　处：《浙江临床医学》2025年第2期225-227,共3页Zhejiang Clinical Medical Journal

基　　金：浙江省基础公益研究计划项目(LGF20H290001)。

摘　　要：目的探讨复方嗜乳酸杆菌对合并胃肠道症状的腹膜透析患者血清及腹腔IL-17,VEGF,TGF-β1水平的影响,为复方嗜乳酸杆菌的临床应用提供科学依据。方法选取2021年6月至2022年9月在杭州市中医院腹膜透析中心接受透析治疗并伴有胃肠道症状的腹膜透析患者(PD)40例。收集患者治疗前(第0天)、治疗中期(第90天)及治疗后期(第180天)的血清及腹透液,并测定血清及腹透液的VEGF、TGF-β1、IL-17水平。通过治疗前后对照研究,观察复方嗜乳酸杆菌对腹膜透析患者血清及腹透液的VEGF、TGF-β1、IL-17的影响。结果经复方嗜酸乳菌片干预治疗后,PD患者血清TGF-β1、VEGF水平下降,腹透液IL-17、TGF-β1、VEGF水平下降,差异具有统计学意义(P<0.05)。血清IL-17表达水平有下降趋势,但差异无统计学意义(P>0.05)。结论复方嗜乳酸杆菌能降低腹膜透析患者腹腔IL-17、TGF-β1及VEGF水平,减轻局部炎症反应,从而保护合并胃肠道症状的腹膜透析患者的腹膜功能。Objective To explore the impact of compound Lactobacillus on serum and peritioneal levels of interleukin-17(IL-17),vascular endothelial growth factor(VEGF)and transforming growth factorβ1(TGF-β1)in peritoneal dialysis patients(PD)with gastrointestinal symptoms,providing a scientific evidenue for its clinical application.Methods Forty patients with gastrointestinal symptoms undergoing dialysis treatment at the Peritoneal Dialysis Center of Hangzhou Traditional Chinese Medicine Hospital June 2021 to September 2022 were selected.Serum and peritoneal dialysis fluid were collected from patients before treatment(day 0),during the middle of treatment(day 90),and at the end of treatment(day 180),and the levels of VEGF,TGF-β1,and IL-17 in serum and peritoneal dialysis fluid were measured.A pre-and post-treatment control study was conducted to observe the effects of compound Lactobacillus on the levels of VEGF,TGF-β1,and IL-17 in the serum and peritoneal dialysis fluid of PD patients.Results After intervention with compound Lactobacillus tablets,the levels of serum TGF-β1 and VEGF in PD patients decreased,and the levels of IL-17,TGF-β1,and VEGF in peritoneal dialysis fluid decreased,with statistically significant differences(P<0.05).The expression level of serum IL-17 showed a decreasing trend,but the difference was not statistically significant(P>0.05).Conclusion Compound Lactobacillus can reduce the levels of IL-17,TGF-β1,and VEGF in the abdominal cavity of peritoneal dialysis patients,alleviate local inflammatory responses,and to some extent,protect the peritoneal function of PD patients with gastrointestinal symptoms.

关 键 词：益生菌制剂 腹膜透析 细胞因子 

分 类 号：R692.5[医药卫生—泌尿科学] R57[医药卫生—外科学]